- Home
- RWAY vs XFOR Comparison
RWAY vs XFOR Comparison
Compare RWAY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RWAY | XFOR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.9M | 332.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RWAY | XFOR |
|---|---|---|
| Price | $9.15 | $3.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $11.08 | ★ $34.67 |
| AVG Volume (30 Days) | 453.9K | ★ 553.0K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 15.32% | N/A |
| EPS Growth | ★ 44.67 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $141,071,000.00 | $33,979,000.00 |
| Revenue This Year | N/A | $1,307.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.16 | ★ N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $8.35 | $1.35 |
| 52 Week High | $11.73 | $26.83 |
Technical Indicators
Market Signals| Indicator | RWAY | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 40.61 |
| Support Level | $8.59 | $3.49 |
| Resistance Level | $9.28 | $3.90 |
| Average True Range (ATR) | 0.27 | 0.24 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 38.64 | 16.23 |
Price Performance
Historical ComparisonAbout RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.